Early studies used polymerase chain reaction (PCR) methods performed on patient blood samples to assess for the presence of KRAS mutation in plasma of patients with confirmed pancreatic adenocarcinoma and in healthy controls (Brychta et al. 2016). Here, KRAS is linked to pancreatic adenocarcinoma.